Last reviewed · How we verify
COR388 capsule
Targeting tau protein aggregation
Targeting tau protein aggregation Used for Alzheimer's disease.
At a glance
| Generic name | COR388 capsule |
|---|---|
| Also known as | atuzaginstat, COR388 HCl |
| Sponsor | Cortexyme Inc. |
| Drug class | Tau protein aggregation inhibitor |
| Target | JNK3 |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 2 |
Mechanism of action
COR388 is a small molecule inhibitor of JNK3, which is involved in tau protein aggregation and neurodegeneration.
Approved indications
- Alzheimer's disease
Common side effects
- Headache
- Nausea
- Diarrhea
Key clinical trials
- GAIN Trial: Phase 2/3 Study of COR388 in Subjects With Alzheimer's Disease (PHASE2, PHASE3)
- A Multiple Ascending Dose Study of COR388 (PHASE1)
- Study of COR388 HCl in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |